What were the key drivers of Eli Lilly's financial performance in 2006?

Eli Lilly's financial performance in 2006 was driven by a 7% increase in worldwide sales, reaching $15.69 billion, primarily fueled by strong growth from newer products like Cymbalta, Forteo, and Byetta, as well as continued strength from Zyprexa. The company also benefited from increased profitability of the Lilly ICOS joint venture and effective cost-containment initiatives, leading to a significant 35% increase in net income.

What are the major risks and challenges facing Eli Lilly, as highlighted in the filing?

The filing highlights several key risks and challenges, including intense competition from other pharmaceutical and generic companies, the potential impact of patent expirations on major products in the coming decade, and increasing government price controls and healthcare cost-containment measures. Additionally, the inherent costs and uncertainties of pharmaceutical research and development, potential safety or efficacy concerns with products, and significant product liability litigation, particularly concerning Zyprexa, pose substantial risks to the company's operations and financial position.

How is Eli Lilly managing its legal and regulatory challenges, particularly regarding Zyprexa?

Eli Lilly is actively managing legal and regulatory challenges through various strategies. For Zyprexa, the company has entered into significant settlement agreements to resolve a substantial majority of product liability claims, although approximately 1,300 claims remain. It is also vigorously defending its Zyprexa patents against generic challenges, with favorable court rulings in the U.S. that have been upheld on appeal. Furthermore, the company is cooperating with government investigations into marketing and promotional practices and is implementing comprehensive compliance programs to ensure adherence to regulations.

What is the company's outlook for 2007, and what key events are expected?

For 2007, Eli Lilly projects earnings per share in the range of $2.89 to $2.99, including the impact of the ICOS acquisition. The company anticipates sales growth in the high single or low double digits, driven by the inclusion of all Cialis revenues post-acquisition and continued growth of key products. Significant investments in R&D and marketing are expected to continue, with a focus on strengthening its pipeline and supporting core product franchises.

LLY 10-K FY2006 Annual Report — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's 2006 10-K filing reveals a company with strong sales growth, driven by key pharmaceutical products, alongside significant investments in research and development. The company reported a substantial increase in net income, despite notable charges related to Zyprexa product liability litigation. Lilly's business is diversified across several therapeutic areas, including neuroscience, endocrine, and oncology, with notable contributions from major drugs like Zyprexa, Cymbalta, and diabetes care products. The company faces ongoing risks, including intense competition, patent expirations, and increasing government regulation and pricing pressures. However, Lilly is actively managing these risks through strategic product development, acquisitions (such as ICOS), and robust legal defenses for its intellectual property. The financial outlook for 2007 projects continued earnings per share growth, supported by expected sales increases and ongoing R&D investment, while acknowledging the potential impact of legal matters and market dynamics.

Key Highlights

1Worldwide sales increased by 7% to $15.69 billion in 2006, driven by strong performance in neuroscience, endocrine, and oncology products.
2Net income rose significantly by 35% to $2.66 billion ($2.45 per share) in 2006, compared to $1.98 billion ($1.81 per share) in 2005.
3Significant charges were incurred, including $450.3 million for asset impairments and restructuring, and $494.9 million related to Zyprexa product liability litigation in 2006.
4Key products like Zyprexa, Cymbalta, and diabetes care products (Humalog, Humulin, Actos, Byetta) continue to be major revenue drivers.
5Research and development investment remained substantial, at approximately 20% of sales, totaling $3.13 billion in 2006.
6The company completed the acquisition of ICOS Corporation in January 2007 to gain full control of Cialis, with an anticipated $300 million charge for acquired in-process R&D.
7Significant legal risks include ongoing patent litigation for key products like Zyprexa, Evista, and Gemzar, and extensive product liability claims, primarily related to Zyprexa.

ELI LILLY & Co Annual Report, Year Ended Dec 31, 2006

Summary

Key Highlights

Frequently Asked Questions